CRISPR Gene Editing Newsletter
Issue #36May 11, 20267 studies

Gold nanoparticles deliver CRISPR and 2.1 kb DNA templates into blood cells

CRISPR gene editing continues to evolve beyond its original form. This week brought advances in delivery methods, safety controls, and applications ranging from brain injury treatment to cancer immunotherapy.

🥇 Gold nanoparticles crack the delivery challenge for large DNA edits

  • Scientists developed gold nanoparticles that can simultaneously deliver CRISPR-Cas9 and DNA templates as long as 2.1 kb into primary human blood cells

  • The system successfully inserted antigen-specific T cell receptor genes into both T cells and hematopoietic stem cells

  • This approach avoids viral delivery methods, potentially reducing safety concerns while enabling complex genetic modifications

Why it matters: Current CRISPR delivery methods struggle with large DNA insertions, especially in hard-to-modify primary cells. This synthetic nanoparticle approach could make sophisticated immune cell engineering more practical for therapies.

Top 20% journal 🔗 Advanced nanobiomed research Journal Article 🗓️ May 6

Key Findings

🧠 Nasal spray delivers brain-targeted CRISPR to reduce inflammation

  • Researchers engineered lipid nanoparticles with antibodies that specifically target brain immune cells (microglia)

  • Intranasal delivery of CRISPR targeting MAPK9 reduced neuroinflammation in mice with traumatic brain injury

  • The treatment showed no detectable toxicity across major organs

💡 This approach could offer a non-invasive way to treat brain inflammation after injury without affecting other organs.

🔒 New safety valve can shut down CRISPR after activation

  • Scientists created RNA inhibitors that can deactivate already-active Cas12a enzymes without chemical modifications

  • The system works through strand displacement, driving activated enzymes back to an inactive state

  • In cells, this approach suppressed uncontrolled editing while preserving intended gene knockout

💡 Post-activation control could make CRISPR therapies safer by preventing runaway editing after the desired changes are made.
🥇 Top 1% journal 🔗 Nucleic acids research Journal Article 🗓️ May 4

🫁 Base editing rescues cystic fibrosis airway cells

  • Base editors delivered by nanoparticles corrected a common CFTR gene mutation (3120+1G>A) in primary airway cells

  • Single-cell analysis showed CFTR expression increased in most airway cell types, especially in ionocytes and secretory cells

  • Functional rescue reached clinically meaningful levels in both immortalized and primary cells

💡 This could provide treatment options for the 10% of cystic fibrosis patients who don't respond to current CFTR modulators.
🥉 Top 5% journal 🔗 JCI insight Journal Article 🗓️ May 8

🎯 Off-the-shelf CAR-T cells show promise against solid tumors

  • Allogeneic CAR-T cells targeting GPC2 and GPC3 demonstrated potent activity in neuroblastoma and liver cancer models

  • CRISPR editing enabled targeted CAR insertion while disrupting genes that cause immune rejection

  • Repeated dosing enhanced antitumor effects without toxicity in preclinical studies

💡 Universal donor CAR-T cells could make this therapy more accessible and effective for solid tumors, where patient-derived cells often perform poorly.

🩸 Gene editing landscape mapped for blood disorders

  • A comprehensive review identified 44 clinical trials testing gene-edited stem cells for blood disorders

  • Only one product (CASGEVY) has been approved to date, with 37 trials focused on hemoglobinopathies

  • Most approaches use CRISPR-Cas9 to edit CD34+ stem cells, targeting BCL11A or γ-globin promoters

💡 Despite promising early results, most gene editing therapies for blood disorders are still in development, highlighting both progress and remaining challenges.
Top 20% journal 🔗 International journal of molecular sciences Review 🗓️ May 4

🦠 CRISPR screen reveals HIV resistance factors

  • A genome-wide screen using replication-competent SIVcpz identified host factors that restrict chimpanzee viruses but not pandemic HIV-1

  • IFITM2, PCED1B, MEFV, and AXIN1 limited SIVcpz replication in human CD4+ T cells

  • These findings reveal barriers that HIV-1 group M strains overcame during their adaptation for pandemic spread

💡 Understanding which human defenses pandemic HIV bypassed could inform strategies for preventing future cross-species viral transmissions.
🔗 Journal of virology Journal Article 🗓️ May 7

Implications

These advances show CRISPR technology maturing from a basic research tool into sophisticated therapeutic platforms. Better delivery methods, safety controls, and targeted applications are addressing key barriers to clinical translation, particularly for complex genetic modifications in hard-to-edit cells.

Studies in this issue

Primary sources used for this newsletter.

  1. Delivering Gene-Editing Tools and Long DNA into Primary Blood Cells Using Gold Nanoparticles Without Viruses
    main storyAdvanced nanobiomed research2026-05-06PMID 42088762
  2. Gene editing screen finds barriers to cross-species spread of chimpanzee SIV virus
    key findingJournal of virology2026-05-07PMID 42095660
  3. A universal safety switch for CRISPR/Cas12a that works without chemicals or outside triggers
    key findingNucleic acids research2026-05-04PMID 42080260
  4. Gene-edited immune cells from donors show strong cancer-fighting effects in solid tumors
    key findingbioRxiv : the preprint server for biology2026-05-07PMID 42094429
  5. Using nasal CRISPR lipid particles to lower brain inflammation after head injury
    key findingbioRxiv : the preprint server for biology2026-05-04PMID 42079190
  6. Current Clinical Trials Using Gene-Edited Blood Stem Cells to Treat Blood Disorders and Immune Deficiencies
    key findingInternational journal of molecular sciences2026-05-04PMID 42074029
  7. Gene editing and nanoparticle delivery in key airway cells for cystic fibrosis treatment
    key findingJCI insight2026-05-08PMID 42100873

Continue reading

All CRISPR Gene Editing issues